Log in

NASDAQ:GILDGilead Sciences Stock Price, Forecast & News

$76.35
+0.29 (+0.38 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$75.65
Now: $76.35
$77.09
50-Day Range
$72.34
MA: $75.28
$77.83
52-Week Range
$60.89
Now: $76.35
$85.97
Volume6.35 million shs
Average Volume18.28 million shs
Market Capitalization$95.77 billion
P/E Ratio19.63
Dividend Yield3.56%
Beta0.7
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Scholar Rock Holding Corporation; Tango Therapeutics; National Cancer Institute; Pfizer, Inc.; Sangamo Therapeutics, Inc.; Gadeta B.V.; HiFiBiO Therapeutics; Agenus Inc.; HOOKIPA Pharma Inc.; Goldfinch Bio, Inc.; and insitro Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Read More
Gilead Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.1Community Rank: 3.3Dividend Strength: 2.5Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.04 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GILD
CUSIP37555810
Phone650-574-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.45 billion
Cash Flow$7.33 per share
Book Value$17.90 per share

Profitability

Net Income$5.39 billion

Miscellaneous

Employees11,800
Outstanding Shares1,254,373,000
Market Cap$95.77 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

How has Gilead Sciences' stock been impacted by COVID-19 (Coronavirus)?

Gilead Sciences' stock was trading at $73.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GILD stock has increased by 3.6% and is now trading at $76.35. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Gilead Sciences?

28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 3 sell ratings, 15 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Gilead Sciences.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Gilead Sciences.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) announced its quarterly earnings results on Thursday, April, 30th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.11. The biopharmaceutical company had revenue of $5.55 billion for the quarter, compared to the consensus estimate of $5.44 billion. Gilead Sciences had a return on equity of 35.44% and a net margin of 21.84%. The business's quarterly revenue was up 5.1% compared to the same quarter last year. During the same period last year, the business earned $1.67 earnings per share. View Gilead Sciences' earnings history.

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences declared a quarterly dividend on Thursday, April 30th. Investors of record on Friday, June 12th will be paid a dividend of $0.68 per share on Monday, June 29th. This represents a $2.72 annualized dividend and a dividend yield of 3.56%. The ex-dividend date of this dividend is Thursday, June 11th. View Gilead Sciences' dividend history.

What price target have analysts set for GILD?

28 Wall Street analysts have issued twelve-month price targets for Gilead Sciences' stock. Their forecasts range from $60.00 to $97.00. On average, they expect Gilead Sciences' stock price to reach $79.65 in the next twelve months. This suggests a possible upside of 4.3% from the stock's current price. View analysts' price targets for Gilead Sciences.

Has Gilead Sciences been receiving favorable news coverage?

Press coverage about GILD stock has been trending somewhat positive on Friday, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Gilead Sciences earned a news sentiment score of 0.7 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Gilead Sciences.

Are investors shorting Gilead Sciences?

Gilead Sciences saw a drop in short interest during the month of June. As of June 15th, there was short interest totaling 24,140,000 shares, a drop of 7.5% from the May 31st total of 26,090,000 shares. Based on an average trading volume of 21,470,000 shares, the short-interest ratio is currently 1.1 days. Approximately 1.9% of the shares of the stock are sold short. View Gilead Sciences' Current Options Chain.

Who are some of Gilead Sciences' key competitors?

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include Walt Disney (DIS), Alibaba Group (BABA), NVIDIA (NVDA), Netflix (NFLX), Intel (INTC), Micron Technology (MU), AbbVie (ABBV), Johnson & Johnson (JNJ), AT&T (T) and Tesla (tsla).

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the following people:
  • Ms. Robin L. Washington, CFO & Exec. VP (Age 56)
  • Dr. John G. McHutchison M.D., FRACP, Chief Scientific Officer and Head of R&D (Age 61)
  • Mr. Gregg H. Alton, Chief Patient Officer (Age 53)
  • Ms. Laura Hamill, Exec. VP of Worldwide Commercial Operations (Age 54)
  • Mr. Daniel O'Day, Chairman & CEO (Age 55)

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Confluence Investment Management LLC (0.10%), Thomasville National Bank (0.01%), First Financial Bank Trust Division (0.01%), Nelson Van Denburg & Campbell Wealth Management Group LLC (0.00%) and Modus Advisors LLC (0.00%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John C Martin, John Francis Cogan, Olsen Per Wold and Richard James Whitley. View institutional ownership trends for Gilead Sciences.

Which institutional investors are selling Gilead Sciences stock?

GILD stock was sold by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC, and Nelson Van Denburg & Campbell Wealth Management Group LLC. Company insiders that have sold Gilead Sciences company stock in the last year include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John Francis Cogan, and Olsen Per Wold. View insider buying and selling activity for Gilead Sciences.

Which institutional investors are buying Gilead Sciences stock?

GILD stock was bought by a variety of institutional investors in the last quarter, including Thomasville National Bank, First Financial Bank Trust Division, and Modus Advisors LLC. View insider buying and selling activity for Gilead Sciences.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $76.35.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $95.77 billion and generates $22.45 billion in revenue each year. The biopharmaceutical company earns $5.39 billion in net income (profit) each year or $6.14 on an earnings per share basis. Gilead Sciences employs 11,800 workers across the globe.

What is Gilead Sciences' official website?

The official website for Gilead Sciences is www.gilead.com.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.